Adverse event profiles and time to onset and resolution with tremelimumab ( t) plus durvalumab (d) in patients with unresectable hepatocellular carcinoma (uhcc) in the phase 3 himalaya trial

dc.contributor.author	De Toni, E. M.
dc.contributor.author	Sangro, B.
dc.contributor.author	Chan, S. L.
dc.contributor.author	Kudo, M.
dc.contributor.author	Kelley, R. K.
dc.contributor.author	-K, Kang Y.
dc.contributor.author	Rimassa, L.
dc.contributor.author	Varela Calvo, María
dc.contributor.author	Dayyani, F.
dc.contributor.author	Makowsky, M.
dc.contributor.author	Marcovitz, M.
dc.contributor.author	Mccoy, C. L.
dc.contributor.author	Negro, A.
dc.contributor.author	Abou Alfa, G.
dc.date.accessioned	2024-07-11T07:29:24Z
dc.date.available	2024-07-11T07:29:24Z
dc.date.issued	2023
dc.identifier.issn	2296-5270
dc.identifier.issn	2296-5262
dc.identifier.uri	https://hdl.handle.net/10651/73147
dc.format.extent	p. 239-240
dc.language.iso	eng
dc.relation.ispartof	Oncology Research and Treatment
dc.rights	©,
dc.source	WOS:001091456900523
dc.title	Adverse event profiles and time to onset and resolution with tremelimumab ( t) plus durvalumab (d) in patients with unresectable hepatocellular carcinoma (uhcc) in the phase 3 himalaya trial
dc.type	conference output

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.